These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33941865)

  • 61. Population screening for prostate cancer and emerging concepts for young men.
    Moul JW
    Clin Prostate Cancer; 2003 Sep; 2(2):87-97. PubMed ID: 15040869
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
    Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Is prostate cancer stage migration continuing for black men in the PSA era?
    Dobbs RW; Greenwald DT; Wadhwa H; Freeman VL; Abern MR
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):210-215. PubMed ID: 28094251
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Is prostate cancer different in black men? Answers from 3 natural history models.
    Tsodikov A; Gulati R; de Carvalho TM; Heijnsdijk EAM; Hunter-Merrill RA; Mariotto AB; de Koning HJ; Etzioni R
    Cancer; 2017 Jun; 123(12):2312-2319. PubMed ID: 28436011
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Continuity of care and advanced prostate cancer.
    Jayadevappa R; Guzzo T; Vapiwala N; Malkowicz SB; Gallo JJ; Chhatre S
    Cancer Med; 2023 May; 12(10):11795-11805. PubMed ID: 36951508
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Decrease in racial disparities in the staging evaluation for prostate cancer after publication of staging guidelines.
    Abraham N; Wan F; Montagnet C; Wong YN; Armstrong K
    J Urol; 2007 Jul; 178(1):82-7; discussion 87. PubMed ID: 17499294
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Limited PSA testing in indigent men in South Texas: an appropriate care or missing a prevention opportunity?
    Liang Y; Du F; Thompson IM; Turner BJ
    Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1489-96. PubMed ID: 22822113
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer.
    Quinn TP; Sanda MG; Howard DH; Patil D; Filson CP
    Cancer; 2021 Aug; 127(16):2974-2979. PubMed ID: 34139027
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation.
    Leapman MS; Wang R; Loeb S; Seibert TM; Gaylis FD; Lowentritt B; Brown GA; Chen R; Lin D; Witte J; Cooperberg MR; Catalona WJ; Gross CP; Ma X
    J Urol; 2023 Apr; 209(4):710-718. PubMed ID: 36753746
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The impact of marital status on tumor aggressiveness, treatment, and screening among black and white men diagnosed with prostate cancer.
    Khan S; Fuzzell L; Langston M; Han Y; Moore JX; Gilbert K; Sutcliffe S; Bensen JT; Mohler JL; Fontham ETH; Song L; Lewis-Thames MW
    Cancer Causes Control; 2024 Mar; 35(3):531-539. PubMed ID: 37919455
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A new approach to understanding racial disparities in prostate cancer treatment.
    Presley CJ; Raldow AC; Cramer LD; Soulos PR; Long JB; Yu JB; Makarov DV; Gross CP
    J Geriatr Oncol; 2013 Jan; 4(1):1-8. PubMed ID: 23828723
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment patterns and survival of low and intermediate-risk prostate cancer in end-stage kidney disease: A retrospective population cohort study.
    Sarabu N; Dong W; Ray AW; Fernstrum A; Prunty M; Ponsky LE; Shoag JE; Shahinian VB; Lentine KL; Koroukian SM
    Cancer Med; 2023 Apr; 12(7):7941-7950. PubMed ID: 36645151
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Isolating the Drivers of Racial Inequities in Prostate Cancer Treatment.
    Hammarlund N; Holt SK; Basu A; Etzioni R; Morehead D; Lee JR; Wolff EM; Gore JL; Nyame YA
    Cancer Epidemiol Biomarkers Prev; 2024 Mar; 33(3):435-441. PubMed ID: 38214587
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inequities in Definitive Treatment for Localized Prostate Cancer Among Those With Clinically Significant Mental Health Disorders.
    Cabral J; Holt SK; Washington SL; Dwyer E; Lee JR; Wolff EM; Gore JL; Nyame YA
    Urol Pract; 2023 Nov; 10(6):656-663. PubMed ID: 37754206
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical presentation and initial management of black men and white men with prostate cancer in the United Kingdom: the PROCESS cohort study.
    Evans S; Metcalfe C; Patel B; Ibrahim F; Anson K; Chinegwundoh F; Corbishley C; Gillatt D; Kirby R; Muir G; Nargund V; Popert R; Wilson P; Persad R; Ben-Shlomo Y
    Br J Cancer; 2010 Jan; 102(2):249-54. PubMed ID: 19935788
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Association between hospital competition and quality of prostate cancer care.
    Jayadevappa R; Malkowicz SB; Vapiwala N; Guzzo TJ; Chhatre S
    BMC Health Serv Res; 2023 Aug; 23(1):828. PubMed ID: 37543580
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Understanding the Role of Urology Practice Organization and Racial Composition in Prostate Cancer Treatment Disparities.
    Agochukwu-Mmonu N; Qin Y; Kaufman S; Oerline M; Vince R; Makarov D; Caram MV; Chapman C; Ravenell J; Hollenbeck BK; Skolarus TA
    JCO Oncol Pract; 2023 May; 19(5):e763-e772. PubMed ID: 36657098
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prostate cancer mortality in Connecticut, Iowa and New Mexico African American men.
    Escobedo LG; Rivas SD; Holmes MD
    Cancer Detect Prev; 2004; 28(5):375-80. PubMed ID: 15542264
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study.
    Parry MG; Nossiter J; Morris M; Sujenthiran A; Skolarus TA; Berry B; Nathan A; Cathcart P; Aggarwal A; van der Meulen J; Trinh QD; Payne H; Clarke NW
    Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):287-292. PubMed ID: 35001083
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comorbidities and the risk of late-stage prostate cancer.
    Fleming ST; McDavid K; Pearce K; Pavlov D
    ScientificWorldJournal; 2006 Jul; 6():2460-70. PubMed ID: 17619718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.